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Anja Saalbach2
The chronic inflammatory skin disease psoriasis is characterized by prominent skin infiltration by neutrophils
and microabscess formation. The adhesion of leukocytes and subsequent transmigration through the activated
endothelium is one prerequisite for the accumulation of these cells in skin. In recent studies, the human Thy-1
(CD90) was characterized as an adhesion molecule on activated endothelial cells (ECs) mediating the adhesion
of neutrophils via the interaction with the b2-integrin Mac-1. Based on these novel findings, we compared the
roles of Thy-1 and ICAM-1 in the adhesion of neutrophils from patients with psoriasis to activated ECs. The
adhesion of peripheral blood neutrophils of patients suffering from psoriasis to Thy-1-transfected cells as well
as to activated, Thy-1-expressing human dermal microvascular ECs (HDMECs) is distinctly increased in
comparison to the adhesion of neutrophils from healthy controls. In contrast, adherence of psoriatic
neutrophils to ICAM-1 transfectants is, if at all, only slightly enhanced compared to healthy controls. The
interaction of healthy as well as psoriatic polymorphonuclear cells to Thy-1 transfectants and HDMECs was
significantly inhibited by blocking Thy-1 on ECs or its receptor Mac-1 on neutrophils, indicating the importance
of this interaction for the adhesion of neutrophils to activated endothelium. In conclusion, our data indicate
that the adhesion of neutrophils to activated ECs mediated by Thy-1/Mac-1 interaction is an important
attachment mechanism facilitating their subsequent migration into lesional psoriatic skin.
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INTRODUCTION
Psoriasis is a common chronic inflammatory skin disease.
There is now increasing evidence for the involvement of
T-cell dysregulation in the development and maintenance of
the psoriatic phenotype. Consequently, many studies focus
on the investigation of the T-cell regulation, but prominent
infiltration and microabscess formation by neutrophils is a
distinct hallmark of psoriasis. It is known that pronounced
parakeratosis is associated with the presence of neutrophils
and that microabscesses of Munro are located exclusively
within areas of parakeratosis (Terui et al., 2000). The
importance of neutrophils for the pathogenesis of psoriasis
is underlined by work from Toichi et al. (2000) describing a
rapid improvement of a long-standing psoriasis during
agranulocytosis. After blood neutrophil recovery, psoriatic
plaques reappear (Toichi et al., 2000). The correlation of
agranulocytosis and blood neutrophil counts with psoriasis
activity indicates that neutrophils are required for the
development of psoriatic plaques. Furthermore, ‘‘flaky skin’’
mice exhibit prominent infiltrates of neutrophils, microabs-
cesses, and hyperproliferation of the epidermis similar to
human psoriasis (Scho¨n et al., 2000). Moreover, in this
model, neutrophil depletion resulted in a dramatic reduction
of epidermal thickness, cutaneous neutrophil infiltration,
downregulation of tumor necrosis factor-a (TNF-a), IL-b, and
a total absence of microabscesses (Scho¨n et al., 2000). Taken
together, T-cell-mediated immunity plays a critical role in
triggering and maintenance of psoriatic lesions, but neutro-
phils are an important pathogenic factor potentiating the
T-cell-associated inflammation (Terui et al., 2000).
The adhesion to endothelial cells (ECs) – as a critical
process in the extravasation of neutrophils into inflamed
perivascular tissue – is mediated by adhesion molecules on
both cell types. Recent studies have emphasized the crucial
role of adhesion molecules (ICAM-1, vascular cell adhesion
molecule-1, endothelial leukocyte adhesion molecule-1
ELAM-1, P-selectin) overexpressed by vascular EC during
the development of psoriasis (Yamasaki et al., 2003). In this
context, the human Thy-1 (CD90) molecule is a very
interesting but barely characterized protein. Recent data
have shown that the human Thy-1 is an activation-associated
cell adhesion molecule expressed on microvascular ECs in
& 2005 The Society for Investigative Dermatology www.jidonline.org 441
ORIGINAL ARTICLE
Received 24 February 2005; revised 26 September 2005; accepted 27
September 2005; published online 22 December 2005
1Department of Dermatology, Venerology and Allergy, University of Leipzig,
Leipzig, Germany and 2Saxon Academy of Science, Leipzig, Germany
Correspondence: Dr Anja Saalbach, Department of Dermatology, Venerology
and Allergy, University of Leipzig, Stephanstrasse 11, 04103 Leipzig,
Germany. E-mail: saalbach@medizin.uni-leipzig.de
Abbreviations: AD, atopic dermatitis; CHO, Chinese hamster ovary; EC,
endothelial cell; HDMEC, human dermal microvascular endothelial cell;
HUVEC, human vascular endothelial cell; MFI, mean fluorescence intensity;
MNC, mononuclear cell; PASI, Psoriasis Area and Severity Index; PBS,
phosphate-buffered saline; PMA, phorbol 12-myristate 13-acetate; PMNC,
polymorphonuclear cell; TNF-a, tumor necrosis factor-a
inflammatory reactions, as well as in tumors (Saalbach et al.,
1999, 2002). We could demonstrate that the human Thy-1 is
involved in the adhesion of neutrophils and monocytes to
activated microvascular ECs via the interaction with the b2-
leukocyte integrin Mac-1 (CD11b/CD18) (Saalbach et al.,
2000; Wetzel et al., 2004). Up to this point, it had been
thought that Mac-1 interacts exclusively with ICAM-1 on the
activated EC, resulting in the firm adhesion of leukocytes to
ECs at sites of inflammation. However, the presence of
additional leukocyte–endothelium adhesion pathways
mediated by interaction of Mac-1 (CD11b/CD18) with a
ligand distinct from ICAM-1 was postulated by different
studies using ICAM-1-deficient mice or antibody-blocking
experiments (Smith et al., 1988; Furie et al., 1991; Sligh et al.,
1993; Xu et al., 1994; Issekutz et al., 1999).
The current data demonstrate that the human Thy-1
molecule is an alternate EC receptor for the leukocyte
integrin Mac-1 that contributes to leukocyte recruitment to
sites of inflammation, thus providing a new pathway for
adhesion and transmigration of neutrophils and monocytes.
To assess the importance of the Thy-1/Mac-1 interaction
in psoriasis, we compared the adhesion of neutrophils
from healthy individuals with neutrophils from patients
suffering from psoriasis vulgaris to Thy-1 and ICAM-1
in vitro. In adhesion assays, peripheral blood neutrophils of
psoriatic patients adhered distinctly more to Thy-1-trans-
fected cells as well as to activated, Thy-1-expressing human
dermal microvascular ECs (HDMECs) than neutrophils from
healthy controls. In conclusion, our results indicate that the
binding of neutrophils to Thy-1 is an important pathway for
neutrophil adhesion to activated endothelium, thereby
contributing to the increased extravasation and prominent
infiltration of neutrophils in the perivascular tissue of
psoriatic lesions.
RESULTS
Thy-1 and ICAM-1 are distinctly expressed on ECs in psoriatic
skin and on activated HDMEC in vitro
ECs were identified by their expression of CD31 (Figure 1).
A massive accumulation of CD11b-expressing cells, mostly
monocytes and neutrophils, can be observed in psoriatic skin
lesion (Figure 1). The adhesion molecules Thy-1 (Figure 1)
and ICAM-1 (Figure 1) are strongly expressed on dermal ECs
in these samples (n¼ 10). A representative example is shown
in Figure 1.
Resting cultured macrovascular ECs from the umbilical
vein (HUVECs), HDMECs, and the simian virus-40-immorti-
lized microvascular EC line, HMEC-1, express moderate
levels of ICAM-1 on the cell surface, as detected by flow
cytometry (Table 1). In contrast, Thy-1 is absent from all
resting ECs (Table 1). Stimulation of HUVECs, HMEC-1s, and
HDMECs with phorbol 12-myristate 13-acetate (PMA)
resulted in an upregulation of ICAM-1 on all cell types. In
contrast to ICAM-1, Thy-1 is only clearly induced on
HDMECs (Table 1). The microvascular EC line HMEC-1 is
not able to express Thy-1 after stimulation (Table 1). A very
small population of the macrovascular ECs from the umbilical
vein express the Thy-1 after stimulation (Table 1). These data
indicate that studies on the physiological role of Thy-1 in ECs
function can be only performed with microvascular ECs.
Psoriatic polymorphonuclear cells adhere more strongly to
Thy-1 than healthy polymorphonuclear cells
In our first attempt to assess the role of the Thy-1/Mac-1
adhesion pathway for the endothelial adhesion in psoriasis,
attachment of polymorphonuclear cells (PMNCs) from
patients with psoriasis vulgaris of the plaque type, from
patients with atopic dermatitis (AD) and from healthy donors
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Figure 1. Thy- and ICAM-1 are strongly expressed on ECs in psoriatic skin
lesions. Human Thy-1, ICAM-1, CD31, and CD11b were detected in cryostat
sections of lesional skin from patients with psoriasis vulgaris using the
avidin–biotin technique. Positive cells are red. Sections were counterstained
with hematoxylin. ECs were localized by their expression of CD31. A massive
accumulation of monocytes and granulocytes was detected by staining with
anti-CD11b antibody (arrowheads). Thy-1 and ICAM-1 were strongly
expressed on ECs (arrow). Similar expression patterns were detected in 10
different specimens.
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Figure 2. Expression of Thy-1 and ICAM-1 on transfected CHO cells. Binding
of (a) an anti-ICAM-1 antibody to CHO cells transfected with ICAM-1 (black
dashed line) and vector (gray line) and (b) an anti-Thy-1 antibody to CHO
cells stably transfected with Thy-1 (gray filled) and vector (gray line) was
detected by flow cytometry. The figure shows a typical histogram of four
independent experiments.
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to Thy-1-, ICAM-1-, and vector-transfected cells was studied.
To validate the adhesion assay, the expression of Thy-1 and
ICAM-1 on the transfectants was analyzed by flow cytometry.
Both cell lines express the antigen on 480% of the cells and
the expression levels (mean fluorescence intensity (MFI)) of
ICAM-1 (MFI¼ 19) and Thy-1 (MFI¼21) were similar in both
cell lines (Figure 2).
In all assays, significantly higher numbers of PMNCs from
psoriatic patients (n¼ 24) adhered to Thy-1-transfected cells,
compared to healthy PMNCs (n¼ 68) or PMNC from patients
with AD (n¼ 12). Not surprisingly, the absolute number of
adherent psoriatic as well as healthy PMNCs differed from
assay to assay. Although the assay-to-assay variability was
relatively high as shown by the standard deviation (SD),
nevertheless these data clearly demonstrated a distinct,
significant increase (Po0.0001) in the Thy-1-mediated
adhesion of psoriatic PMNCs compared to healthy PMNCs
(Figure 3). In contrast, the ICAM-1-mediated adhesion of
psoriatic PMNCs was only slightly enhanced (P¼0.01) when
compared to healthy PMNCs (Figure 3). Taken together, these
data indicate that neutrophils from psoriatic patients display
an enhanced and specific adhesion to Thy-1.
Recently, we have shown that neutrophils adhere to
Thy-1 via the interaction with Mac-1 (Wetzel et al., 2004).
To confirm that the adhesion of psoriatic neutrophils to
Thy-1 transfectants is mediated by this interaction, we studied
the adhesion of psoriatic and healthy PMNCs to Thy-1
transfectants after blocking Thy-1 and its interaction partner
Mac-1. First, we demonstrated that the anti-Thy-1 antibody
B-C9 inhibited the adhesion of neutrophils to Thy-1-
transfected cells, as described recently for the adhesion of
melanoma cells to Thy-1 transfectants (Saalbach et al., 2005).
This mAb B-C9 inhibited the adhesion of PMNCs to Thy-1-
transfected cells to about 60% in comparison to an irrelevant
isotype control antibody (Figure 4). This blocking effect is
specific, as the antibody did not interfere with the binding of
PMNCs to control cells in the absence of Thy-1 (CHO-vector;
Figure 4).
As shown in Figure 5, blocking of Thy-1, the a-chain of
Mac-1 (CD11b), and b2-chain (CD18) significantly reduced
the adhesion of healthy as well as psoriatic neutrophils to
Thy-1 transfectants. In contrast, the antibodies did not
influence the adhesion of neutrophils to vector-transfected
cells, again underlining the specificity of the blocking effect
(data not shown). In aggregate, these blocking experiments
demonstrate that the interaction of Thy-1 with Mac-1 is
involved in the Thy-1-mediated adhesion of healthy as well
as psoriatic neutrophils.
To get more insights into the mechanisms underlying the
enhanced adhesion of psoriatic PMNCs to Thy-1 transfec-
tants, we analyzed the expression of CD11b, CD18 as well as
the activation-dependent epitope of Mac-1 recognized by the
antibody CBRM1/5. Freshly prepared healthy and psoriatic
PMNCs expressed similar levels of CD11b and CD18 (Figure
6a). As conformational changes are critical for the interaction
of the b2-integrins with their ligands (Diamond et al., 1993),
we studied the expression of the activation-dependent
epitope of Mac-1 recognized by the antibody CBRM1/5. As
shown in Figure 6b, this epitope is not detectable on freshly
prepared healthy or psoriatic PMNCs. In contrast, stimulation
Table 1. Expression of ICAM-1 and Thy-1 on resting ECs and phorbolester-activated ECs
HUVECs HMEC-1s HDMECs
Control PMA Control PMA Control PMA
% positive
cells MFI
% positive
cells MFI
% positive
cells MFI
% positive
cells MFI
% positive
cells MFI
% positive
cells MFI
ICAM-1 50.373.5 45.571.0 72.1711.7 80.371.2 31.67114 3.970.3 86.774.1 7.872.0 18713.4 4.770.9 68719.2 10.071.2
Thy-1 2.171.0 1.270.1 11.676.5 6.870.8 2.371.9 1.370.2 2.572.1 1.370.1 6.573.3 3.770.9 43.4712.4 7.272.8
HUVECs, HMEC-1s, and HDMECs were incubated for 48 h with 20 ng/ml phorbolester (PMA) or medium only as control. Expression of CD31, ICAM-1, and
Thy-1 was determined using specific antibodies. An isotype control antibody was used to separate the unspecific fluorescence from the positive cells
expressed as % of the whole cell population (n=5). All cells were positive for CD31 used as a marker for ECs to control the purity of the cells.
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Figure 3. Psoriatic PMNCs adhere more strongly to Thy-1 than healthy
PMNCs. PMNCs were biotin-labeled and added for 60 minutes at 371C to
Thy-1-transfected cells and vector-transfected control cells. After incubation,
unbound cells were removed by gentle washing and adherent cells were fixed
and visualized by incubation with CY
TM
3-conjugated streptavidin. The
number of adherent cells was counted by two different observers blinded
to the experimental protocol, and the mean of both results was calculated.
Thy-1- or ICAM-1-specific adhesion is presented as the number of adherent
cells to vector-transfected cells subtracted from those adherent to the Thy-1-
or ICAM-1-transfected cells. Numbers of adherent PMNCs from patients with
psoriasis vulgaris of the plaque type (black bar, n¼24), from patients with AD
(gray bar, n¼ 12), and from healthy donors (white bar, n¼ 68) to Thy-1-,
ICAM-1-, and vector-transfected CHO cells were determined. The data
represent the mean7SD; *Po0.0001 (Mann–Whitney test).
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of healthy as well as psoriatic PMNCs with phorbolester
significantly increased the expression of the activation-
dependent epitope of Mac-1. Importantly however, there
were no differences in the expression of this epitope
on healthy and psoriatic PMNCs after stimulation with
phorbolester, thus making it unlikely that the enhanced
adhesiveness of psoriatic PMNCs to Thy-1 is solely due to an
increased expression or activation-dependent affinity of the
ligand Mac-1.
Elevated adhesion of psoriatic PMNCs to Thy-1 decreases
during psoriasis standard therapy
The adhesion of PMNCs from 20 patients with psoriasis
vulgaris was studied before and after standard treatment with
topical corticosteroids, dithranol, and UVB for 2 weeks in
order to correlate the adhesion rate of PMNCs to Thy-1-,
ICAM-1-, and vector-transfected Chinese hamster ovary
(CHO) cells with disease activity. Interestingly, after success-
ful treatment of the psoriatic skin lesions as demonstrated by
a reduced Psoriasis Area and Severity Index (PASI) (about
475%), the upregulated Thy-1-specific adhesion was re-
duced significantly in 19 of 20 patients, reaching almost the
levels of healthy control PMNCs (Figure 7a). In contrast, the
adhesion of psoriatic PMNCs to ICAM-1-transfected cells was
not significantly changed during treatment (Figure 7a).
Moreover, a time-course analysis from five patients showed
that the Thy-1-specific adhesion of PMNCs significantly
declined very early during effective antipsoriatic therapy
(Figure 7b). Already 2 days after initiation of the treatment,
the Thy-1-mediated adhesion of neutrophils was reduced.
Subsequently, 6 days after initial treatment, the Thy-1-
mediated adhesion was significantly downregulated (Figure
7b). In contrast, the initial ICAM-1-mediated adhesion of
psoriatic PMNCs was only very slightly increased in
comparison to healthy controls and did not change sig-
nificantly during therapy (Figure 7b).
Psoriatic PMNCs adhere more strongly to activated HDMEC
than healthy PMNCs
So far, we had tested neutrophil adhesion to Thy-1- or ICAM-
1-transfected CHO cells. To confirm the physiological
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Figure 4. The mAb B-C9 inhibits the Thy-1-mediated adhesion of PMNCs.
Adhesion of PMNCs to a confluent monolayer of Thy-1-transfected cells and
vector-transfected control cells was quantified after incubation with the mAb
B-C9 or with an irrelevant isotype control antibody. PMNCs were biotin-
labeled and added to Thy-1-transfected cells and vector-transfected control
cells for 60 minutes at 371C. After incubation, unbound cells were removed
by gentle washing and adherent cells were fixed and visualized by incubation
with CY
TM
3-conjugated streptavidin. The number of adherent cells was
determined as described in Materials and Methods. *Po0.05 (unpaired t-test).
Data represent the mean7SD of three independent experiments.
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Figure 5. Adhesion of psoriatic and healthy neutrophils to Thy-1 transfec-
tants is inhibited by blocking Thy-1 or its receptor Mac-1. Adhesion of
healthy (n¼ 3) as well as psoriatic PMNCs (n¼ 3) chosen at random to a
confluent monolayer of Thy-1-transfected cells and vector-transfected control
cells was detected after incubation of the neutrophils with antibodies against
CD11b or CD18, or with an irrelevant control antibody, respectively. For
blocking Thy-1, transfected cells were incubated with anti-Thy-1 antibody
B-C9 or an isotype control antibody. Adherent cells were counted as
described in Materials and Methods. Adhesion of healthy or psoriatic PMNCs
was set to 100%. The adhesion of PMNCs after blocking Thy-1 or Mac-1 was
expressed as % in comparison to the adhesion of PMNCs with the isotype
control antibody. *Po0.05 (unpaired t-test). Data represent the mean7SD of
three independent experiments.
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Figure 6. Healthy and psoriatic PMNCs similarly express Mac-1. PMNCs
from psoriatic patients (n¼8) and healthy controls (n¼ 10) were prepared as
described in Materials and methods. For stimulation, PMNCs were incubated
for 10 minutes at room temperature with 100 ng/ml phorbolester (PMA). Cells
were washed and analyzed by flow cytometry. (a) Expression of CD11b and
CD18 is depicted as MFI. (b) Expression of the activation-dependent epitope
of Mac-1 recognized by the antibody CBRM1/5 is shown as % positive cells.
n.s. nonsignificant (unpaired t-test).
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relevance of our findings, we studied the adhesion
of psoriatic and healthy PMNCs to HDMECs, which among
many other adhesion molecules also express Thy-1
and ICAM-1 in vivo (Figure 1). As shown in Table 1, Thy-1-
dependent endothelial functions can only be studied in
activated HDMECs. Stimulation of second to third passage
HDMECs with 20 ng/ml PMA for 48 hours resulted in a
distinct induction of Thy-1 and a strong upregulation of
ICAM-1 (Table 1). In contrast, neither HUVEC nor HMEC-1
cell line expressed considerable amounts of Thy-1 after
stimulation (Table 1) HDMECs were washed intensively
before the adhesion assays to prevent carryover of significant
amounts of PMA, which could result in unspecific PMNCs
stimulation.
Importantly, the adhesion of psoriatic PMNCs to Thy-1-
expressing, activated HDMECs was increased significantly
(Po0.001) in comparison to healthy PMNCs (Figure 8), thus
paralleling the increased adhesion of psoriatic PMNCs to
Thy-1 transfectants. Moreover, blocking of Thy-1 on activated
HDMECs or of the Thy-1 receptors Mac-1 on neutrophils
inhibited significantly the adhesion of both healthy and
psoriatic PMNCs, thus clearly demonstrating the Thy-1
dependency of this interaction (Figure 8). Adhesion of
PMNCs to activated HDMECs was not affected by an isotype
control antibody. Furthermore, preincubation of unstimulated
HDMECs (Thy-1-negative) with the mAb B-C9 had no effect
on the adhesion. Thus, Thy-1-mediated adhesion to ECs is
strictly activation dependent (Wetzel et al., 2004; data not
shown).
Soluble mediators of psoriatic mononuclear cells stimulate the
Thy-1-mediated adhesion of healthy PMNCs
In a first attempt to study whether mononuclear cells (MNCs)
might affect the adhesiveness of PMNCs in psoriasis, medium
exchange experiments were performed to test whether
soluble mediators from MNCs are responsible for the
enhanced adhesive capacity of psoriatic PMNCs to Thy-1-
expressing ECs. To this effect, MNCs were prepared from
healthy donors and psoriatic patients and cultured overnight
in serum-free medium. Supernatants were harvested and used
for stimulation of healthy PMNCs. Subsequently, the adhe-
sion of these stimulated PMNCs to Thy-1- as well as vector-
transfected cells was determined.
As shown in Table 2, supernatants of healthy MNCs did
not affect the Thy-1-mediated adhesion of healthy PMNCs. In
contrast, supernatants of psoriatic MNCs significantly en-
hanced the Thy-1-mediated adhesion of healthy PMNCs
(Table 2). To identify soluble mediators responsible for this
effect, we determined the presence of IL-8 and TNF-a in these
supernatants by ELISA.
IL-8 was similarly produced by healthy (190742 pg/ml;
n¼10) and psoriatic MNCs (222718 pg/ml; n¼ 8). TNF-a
was significantly increased in supernatants from psoriatic
MNCs (5707300 pg/ml; n¼8) compared to control samples
(1627105 pg/ml; n¼10). Next, PMNCs were stimulated
with purified TNF-a or IL-8 prior to attachment. Both TNF-a
and IL-8 led to a strong upregulation of the Thy-1-specific
adhesion of healthy PMNCs (Table 2). To prove the role of
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Figure 7. Elevated adhesion of psoriatic PMNCs to Thy-1 decreases during
antipsoriatic standard therapy. The adhesion of PMNCs to Thy-1-, ICAM-1-,
and vector-transfected CHO cells was studied (a) in psoriatic patients (n¼ 20)
before (gray) and after (white) standard treatment, as described in Materials
and Methods (*Po0.001, n.s. nonsignificant determined by the paired t-test),
and (b) in patients (n¼5) in a time-course-dependent manner. *Po0.05,
adhesion of psoriatic PMNCs after 2, 6, or 9 days compared to initial
measurement at day 0 (paired t-test); **Po0.01, healthy versus psoriatic
PMNC on day 0 (unpaired t-test). Thy-1- or ICAM-1-specific adhesion is
presented as the number of adherent cells to vector-transfected control cells
subtracted from those adherent to the Thy-1- or ICAM-1-transfected cells. The
number of adherent cells was counted by two different observers and the
mean of both results was calculated, as detailed in the legend of Figure 3.
Adhesion of healthy PMNCs of at least two different donors per experiment
was set to 100%. The adhesion of psoriatic PMNCs was expressed as % in
comparison to the adhesion of healthy PMNCs.
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Figure 8. Psoriatic PMNCs adhere strongly to activated HDMECs in a
Thy-1-dependent manner. HDMECs were stimulated with PMA to induce
Thy-1 expression on 40–60% of the cells. The number of adherent PMNC
from psoriatic patients (n¼3) and healthy blood donors (n¼ 6) chosen at
random to activated Thy-1-expressing HDMECs was assessed by two
independent observers. Further, HDMECs were preincubated for 0.5 hours
with a function-blocking antibody against Thy-1, CD11b, or CD18 or an
isotype control antibody, or left untreated. The experiments were performed
in duplicate and the number of adherent cells was counted in 10 microscopic
fields. The adhesion of healthy PMNCs to stimulated HDMECs without
preincubation was set to 100%. Data represent the mean7SD of three
independent experiments for psoriatic PMNCs and six independent experi-
ments for healthy PMNCs. *Po0.01 healthy versus psoriatic PMNCs;
#Po0.01 for adhesion after preincubation versus untreated HDMECs
(unpaired t-test).
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these MNC-derived cytokines in the induction of Thy-1-
mediated adhesion of healthy PMNCs, psoriatic MNC super-
natants were preincubated with neutralizing antibodies
against TNF-a or IL-8 prior to the addition to healthy PMNCs.
As shown in Table 2, neutralization of TNF-a or IL-8
significantly reduced the stimulating effect of the supernatant
of psoriatic MNCs on the Thy-1-mediated adhesion. In
summary, these experiments demonstrate that MNCs from
psoriatic patients secrete soluble factors, especially TNF-a,
which in turn activate PMNCs resulting in an increased
adhesion of PMNCs to Thy-1-expressing cells.
DISCUSSION
Psoriasis is an inflammatory skin disease associated with
hyperproliferation of keratinocytes, dermal infiltration of
lymphocytes as well as a massive accumulation of neutro-
phils, leading to epidermal microabscesses. The adhesion of
the leukocytes and subsequent transmigration through the
activated endothelium is one prerequisite for the accumula-
tion of these cells in the skin. Several studies indicate that an
activation of the endothelium in psoriatic skin lesions leads to
an increased expression of cell adhesion molecules such as
ICAM-1, VCAM-1, E-selectin and subsequent formation of an
adhesion-promoting surface (Terajima et al., 1998).
As psoriasis is accepted to be a T-cell-mediated disease,
the regulation of the adhesion of MNCs to ECs has been
investigated intensively. Several studies examined the adhe-
sion of MNCs to psoriatic skin, especially to the dermal
vascular endothelium (Chin et al., 1990a, b; Cai et al., 1996).
MNCs from psoriatic patients bind more avidly to activated
ECs than to non-activated EC (LeRoy et al., 1991; Dunky
et al., 1997; Vora et al., 1997). In contrast, only few data exist
on the adhesion of psoriatic PMNCs, which are also very
prominent in psoriatic skin lesions and are thought to be
responsible for many important features of the disease (Scho¨n
et al., 2000; Terui et al., 2000; Toichi et al., 2000). Barker
et al. (1992) demonstrated an increased adhesion of activated
PMNCs to psoriatic epidermis and vascular ECs. Functional
studies showed an upregulation of the oxidative response and
migratory ability, indicating an activation of psoriatic PMNCs
(Ternowitz, 1986; Biasi et al., 1998). Some authors reported
an increased adhesion of psoriatic PMNCs to artificial
surfaces (Sedgwick et al., 1980; Majewski et al., 1985),
whereas others could not detect any differences in the
adhesion of psoriatic and healthy PMNCs (Biasi et al., 1998).
In summary, although PMNC infiltration and accumulation is
a generally accepted hallmark of psoriasis, the underlying
mechanisms are still unclear.
Recent studies indicate that the Thy-1 molecule, expressed
on activated HDMECs, interacts with the b2-leukocyte
integrin Mac-1 (CD11b/CD18), mediating the adhesion of
PMNCs and monocytes to activated ECs (Wetzel et al., 2004).
Up to this point, it was thought that Mac-1 interacts
predominantly with ICAM-1 on activated ECs, resulting
ultimately in the firm adhesion of leukocytes to ECs at sites
of inflammation. Our recent data demonstrate that – in
addition to ICAM-1 – human Thy-1 is an alternative ECs
receptor for the leukocyte integrin Mac-1, and plays an
important role during adhesion and transmigration of
neutrophils and monocytes to sites of inflammation.
Based on these novel findings, we compared the impact of
Thy-1 during adhesion of neutrophils from patients with
psoriasis to activated ECs.
In situ, Thy-1 expression on ECs could only be observed in
inflammatory reactions, whereas in healthy skin, Thy-1
expression is not detectable on ECs (Saalbach et al., 1999).
Immunohistochemical analysis of psoriatic skin presented in
this paper revealed that Thy-1 as well as ICAM-1 is strongly
expressed on activated dermal ECs. In close apposition to
these ECs, a massive infiltration of CD11b-positive cells was
detected, suggesting a role of Thy-1/ICAM-1/CD11b inter-
actions in the extravasation of leukocytes into psoriatic
lesions. We could demonstrate for the first time that specific
adhesion of PMNCs from psoriatic patients to Thy-1 was
distinctly higher compared to PMNCs from healthy donors.
Additionally, PMNCs from patients suffering from AD,
characterized by a distinct cutaneous inflammation activity
without significant infiltration or activation of neutrophils,
adhere just like healthy PMNCs.
The inhibition of the Thy-1-mediated PMNC adhesion by
functional blocking of Thy-1 proved the specificity of the
adhesion to Thy-1 transfectants. The significant reduction of
the adhesion of psoriatic neutrophils to Thy-1-transfected
cells by blocking either Mac-1 or Thy-1 provided further
evidence for the involvement of the Thy-1/Mac-1 interactions
Table 2. Soluble mediators released by psoriatic
MNCs stimulate the Thy-1-mediated adhesion of
healthy PMNCs
Stimulation with
% adhesion of healthy PMNC
to Thy-1-transfected cells
None 100
TNF-a 6057254.9*
IL-8 6847205*
Supernatant of healthy MNC 103.775.4
Supernatant of psoriatic MNC 183.1727.4*
Supernatant of psoriatic
MNC+isotype antibody (0.5mg/ml)
100
Supernatant of psoriatic MNC+
anti-IL-8 (0.5 mg/ml)
56.378.4*
Supernatant of psoriatic MNC+
anti-TNF-a (0.1 mg/ml)
55.3715.7*
Healthy PMNCs were stimulated with 10 ng/ml TNF-a (n=3), 10 ng/ml IL-8
(n=4), or with supernatants from healthy MNCs (n=6) or psoriatic MNCs
(n=6). Subsequently, the adhesion to Thy-1- and vector-transfected cells
was analyzed. The adhesion of healthy PMNCs without stimulation was
set to 100%. *Po0.01 (unpaired t-test).
For blocking TNF-a or IL-8 in psoriatic MNC supernatants, these were
incubated for 15 min with antibodies against TNF-a (0.1m/ml), IL-8
(0.5 mg/ml), or an irrelevant isotype control antibody. Subsequently, the
supernatants were used to stimulate PMNCs for 30 min and then the
adhesion to Thy-1 transfectants and controls was determined. Data
represent the mean7SD of three independent experiments. *Po0.01
(unpaired t-test).
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in the adhesion of psoriatic neutrophils to Thy-1, as described
recently for healthy neutrophils (Wetzel et al., 2004).
However, blocking of Mac-1 did not result in a complete
inhibition of the Thy-1-mediated adhesion. Recently, the
avb3 integrin was described as a receptor for Thy-1 on
melanoma cells (Saalbach et al., 2005). Several studies
describe the expression of avb3 on neutrophils (Janardhan
et al., 2004). Thus, interaction of Thy-1 with avb3 might be
also involved in adherence of neutrophils to Thy-1.
In contrast, although ICAM-1 has long been thought to be
the most important adhesion molecule on activated ECs to
mediate stable adhesion of leukocytes (Gahmberg, 1997;
Hubbard and Rothlein, 2000), we found only a slight
difference in the adhesion of psoriatic versus healthy or AD
PMNCs to ICAM-1-transfected cells. Different sensitivities of
Thy-1- and ICAM-1-mediated adhesion assays can be
excluded, because of similar expression levels of Thy-1 and
ICAM-1 on the respective cells. Furthermore, PMNCs from 49
healthy donors adhered to Thy-1- and ICAM-1-transfected
cells to a similar extent, suggesting that the affinity of the
recombinant and expressed proteins toward their ligands is
not significantly different.
The b2-integrin, Mac-1, contains an inserted domain
(I-domain), which mainly mediates the binding to its ligands
ICAM-1, fibrinogen, and iC3b. We have demonstrated that
Thy-1 also interacts with the I-domain of Mac-1 (Wetzel
et al., 2004). However, a single I-domain can recognize
multiple and structurally unrelated ligands. Diamond and
Springer (1993) demonstrated that these three ligands of
Mac-1 bind to different, but overlapping regions within the
I-domain. Until now the specific recognition site of Thy-1
within the I-domain of Mac-1 is unknown. The binding of
Thy-1 and ICAM-1 to different regions within the I-domain of
Mac-1 might be responsible for the different adhesion of
psoriatic and healthy neutrophils to Thy1 and ICAM-1.
To gain more insight into the mechanisms underlying the
enhanced binding of psoriatic neutrophils to Thy-1, we
compared the expression of Mac-1 on healthy and psoriatic
PMNCs. In accordance with Sjo¨gren et al. (1999), we did not
see differences in the total expression of the am-chain as well
as b2-chain of Mac-1 on healthy and psoriatic PMNCs.
Furthermore, we can exclude that modifications in the
conformational status of Mac-1 on psoriatic PMNCs are
responsible for the enhanced binding to Thy-1, as the
activation-dependent epitope of Mac-1 recognized by the
antibody CBRM1/5 was also similarly expressed on healthy
and psoriatic PMNCs. Until now, the mechanisms respon-
sible for the increased adhesion of psoriatic PMNCs to Thy-1
remain still unclear.
Interestingly, the increased Thy-1-mediated adhesion was
found to be decreased following standard therapy (UVB,
dithranol, external steroids), suggesting a systemic effect of
these treatment modalities. Cai et al. (1996) reported that
UVB treatment reduced the adhesion of circulating MNCs to
psoriatic plaques treated with UVB as well as to those
shielded from direct UVB exposure. In accordance, UVB
treatment of psoriatic patients downregulated the expression
of skin homing molecules on circulating T cells (Sigmunds-
dottir et al., 2003). The authors concluded that UVB
treatment may affect MNCs as well as PMNCs systemically
(Cai et al., 1996). Our findings that the increased adhesion to
Thy-1-transfected cells decreased during therapy are in line
with these reports. The association of the clinical improve-
ment with a decreased PMNC activation reflected by their
reduced Thy-1-mediated PMNC adhesion highlights the
importance of neutrophil for the maintenance of psoriatic
plaques.
To confirm the physiological relevance of the Thy-1/Mac-
1 interaction in neutrophil adhesion in psoriasis, we studied
the adhesion of psoriatic and healthy PMNCs to HDMECs,
which among many other adhesion molecules also express
Thy-1 and ICAM-1. Adhesion of psoriatic PMNCs to
activated, Thy-1-expressing HDMECs is increased distinctly
compared to PMNCs from healthy controls. The importance
of Thy-1/Mac-1 interactions for the adhesion of psoriatic
PMNC to HDMECs was shown by blocking studies of Thy-1 or
its receptor Mac-1. Previous studies of neutrophil adhesion in
psoriasis could not detect differences in the adhesion of
psoriatic and healthy PMNCs (Biasi et al., 1998; Sjo¨gren et al.,
1999). However, in these studies, human umbilical vein ECs
were used, which express ICAM-1, but not Thy-1. In fact, in
our study, only a slight increase in the adhesion of psoriatic
versus healthy PMNCs to ICAM-1-transfected cells was
detectable.
As neither HUVECs nor the microvascular EC line HMEC-
1 are able to express Thy-1 after stimulation, studies
addressing complex adhesion mechanisms can only be
performed with activated microvascular ECs to ensure the
expression of the relevant adhesion molecules.
In a first attempt to identify the mechanisms leading to the
elevated Thy-1-mediated adhesion of psoriatic PMNCs, we
studied the role of MNCs in the regulation of neutrophil
adhesion. Indeed, conditioned supernatants from psoriatic
MNCs were able to upregulate the Thy-1-mediated adhesion
of healthy PMNCs. This effect was reached after a short time
incubation (0.5 hours) of PMNCs, suggesting that soluble
factors within conditioned supernatants of psoriatic MNCs
induce either conformational changes or translocation of
adhesion molecules from cytoplasmic granules to the cell
surface of PMNCs. The presence of TNF-a and IL-8 in the
supernatant of healthy MNCs, the increase of Thy-1-mediated
adhesion of healthy neutrophils after stimulation with IL-8
and TNF-a, and the reduction of the adhesion of PMNCs to
Thy-1-transfected cells by blocking of TNF-a or IL-8 in the
supernatants of psoriatic MNCs are suggestive of a critical
role of these cytokines in the regulation of neutrophil
adhesion by MNCs.
However, psoriatic MNCs produce significantly more
TNF-a than healthy MNCs. In contrast, in our samples. there
were no significant differences in the amount of IL-8 in the
supernatant of psoriatic and healthy MNCs, suggesting that
TNF-a is mainly responsible for the stimulation of PMNCs
adhesion by conditioned supernatants from psoriatic MNCs.
These data are the first evidence for a potential cross-talk
between psoriatic MNCs and PMNCs resulting, via the
release of soluble mediators like TNF-a, in an increased
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adhesion of psoriatic PMNCs to Thy-1-expressing ECs. This in
turn might be responsible for the stimulation of PMNC
adhesion in psoriasis, leading ultimately to the accumulation
of PMNC in lesional psoriatic skin.
In conclusion, we demonstrated for the first time the
importance of the Thy-1/Mac-1 interaction for the adhesion
of neutrophils to activated EC in psoriasis. Based on these
results, the Thy-1/Mac-1 interaction may be important for the
massively enhanced attachment of neutrophils to activated
EC and their subsequent transmigration and accumulation of
neutrophils in lesional psoriatic skin. These data are in line
with the observation of the reduction of epidermal thickness
and neutrophil accumulation in flaky skin mice after
blockade of Mac-1 (Scho¨n et al., 2000). In this regard, Thy-
1/Mac-1 interactions might not only serve as a parameter of
neutrophil activation and a predictor for disease activity in
psoriasis, but might also be an interesting target for novel
therapeutic strategies designed to intervene with neutrophil
influx into psoriatic skin.
MATERIALS AND METHODS
Patients
The study was approved by the University of Leipzig Ethics
Committee (206/2002). The trial conformed to the principles of the
Declaration of Helsinki Principles and was conducted in accordance
with the principles of Good Clinical Practice. All patients gave their
consent prior to their enrollment into the study.
Patients with systemic medication at the beginning of the study or
abnormal leukocyte counts, C-reactive protein, and erythrocyte
sedimentation rate were excluded from the study.
Patients with plaque type psoriasis aged 18 years or above (eight
male and 16 female patients, mean age 52 years, range 27–93 years),
which had been refractory to topical treatment with external
glucocorticoids or vitamin D3 analogs in the last 4 weeks, were
included in the study. Disease activity was assessed in all patients
using the PASI. The PASI score is based on an assessment of the
percentage involvement in each of the major body portions (head,
trunk, and upper and lower limbs) together with indices of erythema,
induration, and scaling (Fredriksson and Pettersson 1978). Patient
characteristics are summarized in Table 3. The adhesion of PMNCs
from 24 psoriatic patients was determined before the beginning of
the treatment. In addition, the adhesion of PMNCs from 20 patients
was compared before and after successful antipsoriatic therapy as
determined by PASI reduction 475%. All patients were treated for
14 days with dithranol, external betamethason, and UVB photo-
therapy in a similar manner. Patients receiving additional therapies
as indicated in Table 3 were excluded from the analysis of post-
therapy cell adhesion.
In certain experiments (eg blocking studies), subsets of patients or
controls were chosen at random (Figure 5).
Patients with AD aged 18 years or above (four male and eight
female patients, mean age 32 years, range 18–59 years) according to
the criteria of Hanifin and Rajka (1980) suffered from moderate to
severe AD (affecting 410% of body surface area) resistant to
conventional outpatient treatment with emollients, topical corticos-
teroids, and phototherapy. A minimum disease severity score
(severity scoring of AD, SCORAD) of 25 was required for inclusion.
Patient characteristics and severity of the disease are summarized in
Table 3. The adhesion of PMNCs from these patients was determined
before beginning the treatment.
Healthy individuals free of any medication (n¼ 68) were
included in the study as controls (45 female and 23 male subjects,
mean age 35 years, range 25–52 years).
Monoclonal antibodies
The following purified, murine mAbs were obtained from Beckman
Coulter (Krefeld, Germany): Bear1 (anti-CD11b), 84H10 (anti-
CD54), 1F11 (anti-CD31), and IgG1 isotype control. The antibody
CBRM1/5 was purchased from eBioscience (San Diego, CA).
Dichlorotriazinyl-amino-fluorescein-labeled goat anti-mouse and
phycoerythrin- and CYTM3-labeled streptavidin was purchased from
Beckman Coulter.
The mAb AS02 (anti-Thy1) was used as hybridoma cell culture
supernatant (Saalbach et al., 1996, 1998).
The functionally blocking, murine mAb against IL-8 (clone 52E8)
was kindly provided by Professor Sticherling (University Leipzig,
Germany; Sticherling et al., 1989, 1991). The anti-TNF-a antibody
was purchased from R&D (Minneapolis, MN)
Cell preparation and culture conditions
For isolation of PMNCs, whole blood was incubated with dextran
M70 (2% final concentration; Sigma-Aldrich, Taufkirchen, Germany)
for 60 minutes at room temperature. The plasma was removed and
PMNCs were separated by Ficoll density gradient centrifugation
(lymphocyte separation medium, r¼ 1.077 g/ml; MP-Biomedicals,
Aurora, OH) at 800 g for 20 minutes. The pellet containing PMNC
was incubated with aqua dest for 1 minute to lyse the remaining
erythrocytes. Finally, PMNCs were washed twice with phosphate-
buffered saline (PBS).
MNCs from healthy donors and patients with psoriasis vulgaris of
plaque type were isolated by Ficoll density gradient centrifugation
(lymphocyte separation medium, r¼ 1.077 g/ml; MP-Biomedicals)
at 800 g for 20 minutes. MNCs were washed three times with PBS,
resuspended in RPMI without serum, and cultured for 24 hours. The
culture supernatant was centrifuged to remove cells and frozen at
801C until use for stimulation of PMNCs.
Transfected CHO cells were cultured in DMEM/RPMI 1640 (1:1)
with 10% fetal calf serum, 1% ascorbic acid, and 1% penicillin/
streptomycin at 371C, 5% CO2, and passaged after reaching
confluence using 0.05% trypsin and 0.02% EDTA. ICAM-1-
transfected CHO cells were kindly provided by Dr May (German
Heart Center, Munich, Germany).
HDMECs were prepared from human foreskin as previously
described (Saalbach et al., 2000). Experiments were conducted
with cells in passages 2–3. HDMEC cultures were characterized
by their typical cobblestone morphology using light microscopy
and expression of CD31 (platelet endothelial CAM-1) by
flow cytometry. HUVECs were prepared according to standard
protocols (Jaffe et al., 1973). The EC line HMEC-1 (Ades
et al., 1992) and HUVECs and HDMECs were cultured in
microvascular EC basal medium (EBM-MV kit system, PromoCell,
Germany) supplemented with 5% fetal bovine serum, 10 ng/ml
epidermal growth factor, 0.4% EC growth supplement/heparin,
1mg/ml hydrocortisone with 50 mg/ml gentamicin, and 50 ng/ml
amphotericin-B (growth media) in a humidified atmosphere at 371C
and 5% CO2.
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Table 3. Characterization of patients
Psoriasis
Number Age (years) Sex
Duration of psoriasis in
years
Severity of disease
(PASI)
Non-psoriatic
medication
Anti-psoriatic medication
different from standard
1 56 Male 36 12.4 —
2 55 Female 3 7.6 —
3 64 Female 48 12.2 —
4 30 Female 25 15.3 —
5 30 Male 4 9.4 —
6 48 Male 8 9.6 —
7 38 Female 29 22.4 —
8 75 Female 2 12.4 —
9 44 Female 23 13.6 —
10 30 Male 5 10.7 —
11 28 Female 5 5.2 —
12 28 Female 0 18.2 Metoprolol
13 54 Female 29 10.2 Metformin, ca-valproate,
nitrendipine
14 36 Female 23 24.3 Valsartan
15 81 Female 1 13.6 Captopril, levothyroxine
16 39 Female 13 10.4 Rofecoxib
17 71 Female 53 12.0 Hydrochlorothiazide, aspirin,
torasemide, digitoxin,
phenprocoumon,
artovastatin, ramipril,
metformin
18 51 Female 16 15.6 Perazin, ranitidine, zotepine,
carbamazepine, biperiden,
furosemide
19 92 Female 80 8.2 Thiamazole, N-
acetylcysteine, ramipril,
felopidine
20 41 Male 30 18.2 Carbamazepine, diazepam
21 60 Female 39 16.4 — Fumaric acid esters
22 53 Male 24 18.4 Artovastatin, levothyroxine,
candesartan cilexetil,
glibenclamide
Methotrexate
23 69 Female 35 21.4 — Cyclosporin A, rofecoxib
24 42 Male 22 20.3 Rabeprazole Cysclosporin A
Atopis dermatis (AD)
Number Age (years) Sex
Duration of atopic
dermatitis in years
Severity of disease
(SCORAD)
Non-atopic medication
1 21 Male 5 42 —
2 39 Male 15 68 —
3 23 Female 20 52 —
4 23 Female 20 46 —
5 58 Female 2 48 Glibenclamide, metoprolol,
aspirin,
6 23 Male 18 42 —
7 19 Female 16 34 —
Table 3 continued on following page
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Flow cytometry analysis
Cells were harvested and washed twice in PBS. Cells (2 105) were
incubated with 1mg of the different mAbs for 60 minutes at 41C. After
washing twice with PBS/Gelafusal (Serumwerke Bernburg, Ger-
many)/sodium azide, cells were incubated with dichlorotriazinyl-
amino-fluorescein-labeled goat anti-mouse secondary antibody
(diluted 1:200 in PBS). Finally, cells were washed twice with PBS,
and antibody binding was analyzed by flow cytometry (Epics XL,
Beckman Coulter).
Immunhistochemical analysis
For detection of Thy-1, CD11b, ICAM-1, and CD31, cryostat
skin sections of patients with psoriasis of the plaque type
were incubated with the mAb AS02 (Saalbach et al., 1998), anti-
CD31, anti-ICAM-1, and anti-CD11b antibody, respectively. Positive
cells were identified using the avidin–biotin complex technique
according to the manufacturer’s protocol (supersensitive multilink
alkaline phosphatase ready-to-use detection system, Biogenix,
San Ramon, CA). Bound proteins were detected by color reaction
applying New Fuchsin substrate system (DAKO, Hamburg,
Germany).
Cell adhesion assays
For cell adhesion assays, CHO cells transfected with Thy-1, ICAM-1,
or control vector as well as HDMECs stimulated with PMA (20 ng/ml)
were used. Cells were seeded on chamber slides (NUNC,
Wiesbaden, Germany) and cultured for 24–48 hours at 371C and
5% CO2. After reaching a confluent cell monolayer, the transfected
cells were fixed by incubation with ice-cold methanol and stored at
201C. HDMECs were used in cell adhesion assays directly after
reaching a confluent cell monolayer.
Peripheral PMNCs were isolated and biotinylated with D-
biotinoyl e-aminocaproic acid hydroxysuccinimide ester (Roche
Biochemicals, Mannheim, Germany) according to the manufac-
turer’s protocol. In stimulation experiments, PMNCs were preincu-
bated with the respective stimulus for 30 minutes at 371C before
adding to the cell monolayer. For blocking TNF-a or IL-8
functionally, blocking antibodies were added to the supernatant of
psoriatic MNCs before the supernatant was used for the stimulation
of PMNCs. After washing three times with PBS, 2 105 of the
respective PMNCs in RPMI 1640 were added to each well and
incubated for 30 minutes at 371C. Unbound cells were removed by
several washes with RPMI 1640 and adherent cells were fixed with
ice-cold methanol for 10 minutes at 201C, air-dried, and blocked
by incubation with PBS/1% BSA. Subsequently, adherent biotiny-
lated cells were visualized by incubation with CYTM3-conjugated
streptavidin (Beckman Coulter, 1:500 in PBS/1% BSA) for 60 minutes
at room temperature, and finally washed twice with PBS. The
number of cells that adhered to the respective confluent cell
monolayer was counted in 10 microscopic fields (magnification
 20) by two independent observers masked to the treatment/
disease. The mean of the results of both independent observers was
calculated for each experiment and used for computing the statistical
analysis.
There were no significant differences in the absolute number of
adherent healthy and psoriatic PMNCs counted by two independent
observers, showing that there are no significant (P¼ 0.85) inter-
observer variations (Figure S1). To adjust for individual differences,
the mean of the results of both independent observers was calculated
for each experiment.
Next, we tested the adhesion of PMNCs from different healthy
donors. In the same experiment, we determined the adhesion
of healthy PMNCs from four different donors. This experiment
revealed a low SD and an error of the SD of less than
15% (Figure S2). Based on these results, adhesion of PMNCs
from different healthy individuals (two per experiment) was used
8 19 Female 16 45 —
9 24 Male 23 72 —
10 29 Male 25 68 —
11 22 Female 19 51 —
12 25 Female 23 41 —
13 20 Female 18 48 —
14 23 Male 20 37 —
15 20 Male 6 52 —
Patients aged 18 years or above with a clinical diagnosis of plaque type psoriasis that had been refractory to topical treatment with external steroids or
vitamin D3 analog in the previous 4 weeks and patients with AD affecting 410% of body surface area uncontrolled by conventional treatment with
emollients, topical corticosteroids, and phototherapy were included in the study. Psoriasis Area and Severity Index (PASI) or the severity scoring of AD
(SCORAD) were assessed on the day of study enrollment and on indicated intervals. Patients with abnormal leukocyte count, C-reactive protein, and
erythrocyte sedimentation rate were excluded. The adhesion of PMNCs from 24 psoriatic patients and 12 patients with AD was determined before beginning
the treatment. Additionally, the adhesion of PMNCs from psoriatic patients 1–20 was also investigated after successful anti-psoriatic therapy as determined by
PASI reduction 475%. All patients were treated with dithranol, external steroid, and UVB phototherapy in a similar manner. Patients receiving additional
anti-psoriatic therapies were excluded from this part of the study (patients 21–24).
Table 3. Continued
Psoriasis
Number Age (years) Sex
Duration of atopic
dermatitis in years
Severity of disease
(SCORAD)
Non-atopic
medication
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as control to compare the adhesion of psoriatic PMNCs and healthy
PMNCs.
Not surprisingly, the absolute number of adherent PMNCs from
psoriatic or healthy donors differed from assay to assay. Therefore,
the adhesion of ‘‘healthy PMNCs’’ was set to 100% and the change
in the adhesion of ‘‘psoriatic PMNCs’’ was expressed as % compared
to healthy PMNCs.
To present the Thy-1- or ICAM-1-specific adhesion, the number
of cells adherent to vector-transfected cells was subtracted from
those adherent to the Thy-1- or ICAM-1-transfected cells.
Statistical evaluation
First, the distribution of all data was tested using the Kolmogorov–
Smirnov test. Normally distributed data were analyzed by the t-test.
The paired t-test was used for data before and after treatment of the
same patient group. The other data were analyzed by the unpaired
t-test. Non-normally distributed data were evaluated by the
Mann–Whitney test.
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SUPPLEMETARY MATERIAL
Figure S1. PMNCs were prepared from a healthy blood donor and a psoriatic
patient. The number of adherent PMNCs to vector-transfected control cells
and Thy-1-transfectants was determined in ten microscopic fields (20
magnification) by two independent observers blinded to the treatment
conditions. For the presentation of the Thy-1-specific adhesion, the number
of adherent cells to vector-transfected control cells was subtracted from those
to Thy-1-transfectants. The gray bar represents the mean of adherent cells
counted by the two observers.
Figure S2. PMNCs were purified from different healthy blood donors (n¼ 4).
The adhesion of PMNCs to vector-transfected control cells (CHO.vec), Thy-1-
transfectants (CHO.Thy-1) and ICAM-1-transfectants (CHO.ICAM1) was
determined. For the presentation of the Thy-1- or ICAM-1-specific adhesion,
adhesion to vector-transfected control cells was subtracted from the adhesion
to Thy-1- or ICAM-1-transfectants (CHO.Thy1-CHO.vec; CHO.ICAM1-
CHO.vec). The error of the SD is less than 15%.
REFERENCES
Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC et al.
(1992) HMEC-1: establishment of an immortalized human microvascular
endothelial cell line. J Invest Dermatol 99:683–90
Barker JN, Groves RW, Allen MH, MacDonald DM (1992) Preferential
adherence of T lymphocytes and neutrophils to psoriatic epidermis. Br J
Dermatol 127:205–11
Biasi D, Carletto A, Caramaschi P, Bellavite P, Maleknia T, Scambi C et al.
(1998) Neutrophil functions and IL-8 in psoriatic arthritis and in
cutaneous psoriasis. Inflammation 22:533–43
Cai JP, Harris K, Falanga V, Taylor JR, Chin YH (1996) UVB therapy decreases
the adhesive interaction between peripheral blood mononuclear cells
and dermal microvascular endothelium, and regulates the differential
expression of CD54, VCAM-1, and E-selectin in psoriatic plaques. Br J
Dermatol 134:7–16
Chin YH, Falanga V, Cai JP (1990a) Lymphocyte adhesion to psoriatic
dermal endothelium: mechanism and modulation. J Invest Dermatol
95:29S–31S
Chin YH, Falanga V, Taylor JR, Cai JP, Bax J (1990b) Adherence of human
helper/memory T-cell subsets to psoriatic dermal endothelium. J Invest
Dermatol 94:413–7
Diamond MS, Garcia-Aguilar J, Bickford JK, Corbi AL, Springer TA (1993) The
I domain is a major recognition site on the leukocyte integrin Mac-1
(CD11b/CD18) for four distinct adhesion ligands. J Cell Biol
120:1031–43
Diamond MS, Springer TA (1993) A subpopulation of Mac-1 (CD11b/CD18)
molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen.
J Cell Biol 120:545–56
Dunky A, Neumuller J, Menzel J (1997) Interactions of lymphocytes from
patients with psoriatic arthritis or healthy controls and cultured
endothelial cells. Clin Immunol Immunopathol 85:297–314
Fredriksson T, Pettersson U (1978) Severe psoriasis – oral therapy with a new
retinoid. Dermatologica 157:238–44
Furie MB, Tancino MC, Smith CW (1991) Monoclonal antibodies to leukocyte
integrins CD11a/CD18 and CD11b/CD18 or intercellular adhesion
molecule-1 inhibit chemoattractant-stimulated neutrophil transendothe-
lial migration in vitro. Blood 78:2089
Gahmberg CG (1997) Leukocyte adhesion: CD11/CD18 integrins and
intercellular adhesion molecules. Curr Opin Cell Biol 9:643–50
Hanifin JM, Rajka G (1980) Diagnostic features of atopic dermatitis. Acta
Derm Venereol 92(Suppl.):44–7
Hubbard AK, Rothlein R (2000) Intercellular adhesion molecule-1
(ICAM-1) expression and cell signaling cascades. Free Radic Biol Med
28:36671–5
Issekutz AC, Rowter D, Springer TA (1999) Role of ICAM-1 and ICAM-2 and
alternate CD11/CD18 ligands in neutrophil transendothelial migration.
J Leukoc Biol 65:117
Jaffe EA, Nachmann RL, Becker CG, Mimick CR (1973) Culture of
human endothelial cells derived from umbilical veins. J Clin Invest
52:2745
Janardhan KS, Appleyard GD, Singh B (2004) Expression of integrin subunits
alphav and beta3 in acute lung inflammation. Histochem Cell Biol
121:383–90
LeRoy F, Brown KA, Greaves MW, Vora AJ, Slavin B, Robinson M et al. (1991)
Blood mononuclear cells from patients with psoriasis exhibit an
enhanced adherence to cultured vascular endothelium. J Invest
Dermatol 97:511–6
Majewski S, Jablonska S, Langner A, Pawinska M, Szmurlo A (1985) The
adherence to human endothelium and plastic of neutrophils from
psoriatic patients, and the effects of psoriatic patients’ sera on normal
neutrophils. Br J Dermatol 112:655–62
Saalbach A, Anderegg U, Schnabel E, Herrmann K, Haustein U-F (1996)
A novel fibroblast specific antibody. Properties and specificities. J Invest
Dermatol 106:1314
Saalbach A, Haustein UF, Anderegg U (2000) A ligand of human thy-1 is
localized on polymorphonuclear leukocytes and monocytes and
mediates the binding to activated thy-1-positive microvascular endothe-
lial cells and fibroblasts. J Invest Dermatol 115:882–8
Saalbach A, Hildebrandt G, Haustein UF, Anderegg U (2002) The Thy1/Thy-
1-ligand-interaction is involved in binding of melanoma cells to
activated Thy-1-positive microvascular endothelial cells. Microvasc
Res 64:86–93
Saalbach A, Kraft R, Herrmann K, Haustein U-F, Anderegg U (1998) The
monoclonal antibody AS02 recognizes a protein on human fibroblasts
being highly homologous to Thy-1. Arch Dermatol Res 290:360
Saalbach A, Wetzel A, Haustein UF, Sticherling M, Simon JC, Anderegg U
(2005) Interaction of human Thy-1 (CD 90) with the integrin avb3
(CD51/CD61): an important mechanism mediating melanoma cell
adhesion to activated endothelium. Oncogene 24:4710–20
Saalbach A, Wetzig T, Haustein UF, Anderegg U (1999) Detection of human
soluble Thy-1 in serum by ELISA. Fibroblasts and activated endothelial cells
are a possible source of soluble Thy-1 in serum. Cell Tissue Res 298:307–15
Scho¨n M, Denzer D, Kubitza RC, Ruzicka T, Schon MP (2000) Critical role of
neutrophils for the generation of psoriasiform skin lesions in flaky skin
mice. J Invest Dermatol 114:976–83
Sedgwick JB, Bergstresser PR, Hurd ER (1980) Increased granulocyte
adherence in psoriasis and psoriatic arthritis. J Invest Dermatol 74:
81–4
www.jidonline.org 451
A Wetzel et al.
Increased Neutrophil Adhesion to Thy-1 in Psoriasis
Sigmundsdottir H, Gudjonsson JE, Valdimarsson H (2003) The effects
of ultraviolet B treatment on the expression of adhesion molecules
by circulating T lymphocytes in psoriasis. Br J Dermatol 148:
996–1000
Sjo¨gren F, Ljunghusen O, Baas A, Coble BI, Stendahl O (1999) Expression and
function of beta 2 integrin CD11B/CD18 on leukocytes from patients
with psoriasis. Acta Derm Venereol 79:105–10
Sligh Jr JE, Ballantyne CM, Rich SS, Hawkins HK, Smith CW, Bradley A et al.
(1993) Inflammatory and immune responses are impaired in mice
deficient in intercellular adhesion molecule 1. Proc Natl Acad Sci USA
90:8529
Smith CW, Rothlein R, Hughes BJ, Mariscalco MM, Rudloff HE, Schmalstieg
FC et al. (1988) Recognition of an endothelial determinant for CD18-
dependent human neutrophil adherence and transendothelial migration.
J Clin Invest 82:1746
Sticherling M, Bornscheuer E, Schroder JM, Christophers E (1991) Localiza-
tion of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in
normal and psoriatic skin. J Invest Dermatol 96:26–30
Sticherling M, Schroder JM, Christophers E (1989) Production and character-
ization of monoclonal antibodies against the novel neutrophil activating
peptide NAP/IL-8. J Immunol 143:1628–34
Terajima S, Higaki M, Igarashi Y, Nogita T, Kawashima M (1998) An
important role of tumor necrosis factor-alpha in the induction of
adhesion molecules in psoriasis. Arch Dermatol Res 290:246–52
Ternowitz T (1986) Monocyte and neutrophil chemotaxis in psoriasis.
Relation to the clinical status and the type of psoriasis. J Am Acad
Dermatol 15:1191–9
Terui T, Ozawa M, Tagami H (2000) Role of neutrophils in induction of acute
inflammation in T-cell-mediated immune dermatosis, psoriasis: a
neutrophil-associated inflammation-boosting loop. Exp Dermatol 9:1–10
Toichi E, Tachibana T, Furukawa F (2000) Rapid improvement of psoriasis
vulgaris during drug-induced agranulocytosis. J Am Acad Dermatol
43:391–5
Vora AJ, Kidd D, Miller DH, Perkin GD, Hughes RA, Ellis BA et al. (1997)
Lymphocyte–endothelial cell interactions in multiple sclerosis: disease
specificity and relationship to circulating tumour necrosis factor-alpha
and soluble adhesion molecules. Mult Scler 3:171–9
Wetzel A, Chavakis T, Preissner KT, Sticherling M, Haustein UF, Anderegg U
et al. (2004) Human Thy-1 (CD 90) on activated endothelial cells is a
counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18).
J Immunol 172:3850–9
Xu HJ, Gonzalo A, Pierre YS, Williams IR, Kupper TS, Cotran RS et al. (1994)
Leukocytosis and resistance to septic shock in intercellular adhesion
molecule-1 deficient mice. J Exp Med 180:9
Yamasaki E, Soma Y, Kawa Y, Mizoguchi M (2003) Methotrexate inhibits
proliferation and regulation of the expression of intercellular adhesion
molecule-1 and vascular cell adhesion molecule-1 by cultured human
umbilical vein endothelial cells. Br J Dermatol 149:30–8
452 Journal of Investigative Dermatology (2006), Volume 126
A Wetzel et al.
Increased Neutrophil Adhesion to Thy-1 in Psoriasis
